Staphylococcus Aureus Osteomyelitis Mechanisms and Treatments

Staphylococcus aureus osteomyelitis is a serious infection of the bone characterised by persistent bacterial colonisation, tissue destruction and impaired healing. The pathogen exploits multiple survival strategies within the bone microenvironment, including adherence to bone‐forming cells (osteoblasts), invasion of osteocytes and osteoclasts, formation of protective biofilms on bone and implant surfaces, and transition into dormant small‐colony variants that withstand antibiotic pressure. These adaptations lead to chronic inflammation, bone resorption and impaired remodelling driven by an imbalance between osteoblastic bone formation and osteoclastic bone degradation. Conventional management relies on surgical debridement to remove necrotic bone and high‐dose, prolonged antibiotic regimens. However, treatment failure remains high owing to limited drug penetration into biofilm and bone niches, antibiotic tolerance mechanisms, and the emergence of resistant strains. Recent advances aim to refine diagnosis through enhanced bacterial quantification, to disrupt protective niches by targeting biofilm components or metabolic pathways unique to quiescent cells, and to harness local delivery systems that concentrate antimicrobials at the infection site. Immunomodulatory strategies seek to mitigate collateral bone damage by tempering host inflammatory pathways while preserving antimicrobial defences. Taken together, these integrated approaches offer a pathway towards improved clearance of S. aureus from bone tissue, reduced recurrence rates and preservation of skeletal integrity.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Staphylococcus Aureus Osteomyelitis Mechanisms and Treatments publication trend

The graph below shows the total number of articles in staphylococcus aureus osteomyelitis mechanisms and treatments across all publications each year (not limited to Nature Index journals).

Technical terms

Biofilm: A structured community of bacteria embedded in a self‐produced polymeric matrix that enhances resistance to antibiotics and host defences.

Small‐colony variant (SCV): A slow-growing bacterial phenotype with reduced metabolism and increased tolerance to antibiotics, often associated with chronic infection.

Osteoblast: A bone-forming cell responsible for synthesis of new bone matrix and mineralisation.

Osteoclast: A bone-resorbing cell that degrades mineralised matrix during bone remodelling.

Colony forming unit (CFU): A measure of viable bacteria based on their ability to grow into visible colonies in culture.

References

1. Staphylococcus aureus vs. Osteoblast: Relationship and Consequences in Osteomyelitis. Frontiers in Cellular and Infection Microbiology (2015).
2. Novel Insights into Staphylococcus aureus Deep Bone Infections: the Involvement of Osteocytes. mBio (2018).
3. Staphylococcus aureus Infects Osteoclasts and Replicates Intracellularly. mBio (2019).
4. Staphylococcus aureus biofilms decrease osteoblast viability, inhibits osteogenic differentiation, and increases bone resorption in vitro. BMC Musculoskeletal Disorders (2013).
5. Mechanisms of Antibiotic Failure During Staphylococcus aureus Osteomyelitis. Frontiers in Immunology (2021).
6. Rapid bacterial evaluation beyond the colony forming unit in osteomyelitis. eLife (2024).
7. Flourishing Antibacterial Strategies for Osteomyelitis Therapy. Advanced Science (2023).